Patience pays off with Novo Nordisk
Our ability to take a long-term view on the prospects of the Danish healthcare firm was a crucial component of our decision to add it to the Henderson EuroTrust portfolio in 2017.
6 minute read
- Novo Nordisk is currently a star of the pharmaceutical sector, but in 2016 it went through a challenging period amid strong competition.
- Our analysis suggested that a falling share price did not do justice to the company’s potential – and we opted to invest.
- Since then, Novo Nordisk has hit the headlines with weight loss drug Wegovy and spotlighted the innovative capabilities available in Europe.
Adopting a long-term view can be a powerful force in investment management, but its strength can be amplified when fund managers identify company management with the same focus.
Danish drugmaker Novo Nordisk is hitting headlines now – raising its profit guidance and propelling itself to become Europe’s largest listed company by market capitalisation – but this wasn’t the case when we invested in the firm back in 2017.
During 2016, we witnessed the company’s shares drop 37% and its long-serving chief executive, Lars Rebien Sorensen, announce he would step down early as competition from the US was putting pressure on the insulin maker. But for us this period of uncertainty presented a compelling opportunity for Henderson EuroTrust (HNE) to gain a position in the pharmaceutical firm. Examining, but ultimately setting aside the pressure Novo appeared to be under, our research process identified a business with huge potential.
Novo developed a diabetes medication called Semaglutide in 2012, with the drug securing approval in 2017. It revolutionised the treatment of Type 2 diabetes, with scientific studies proving it was able to control blood sugar levels. However, early evidence also indicated that it could help with weight loss and may be able to improve cardiovascular outcomes and other common co-morbidities of diabetes.
Our investment thesis was also partly predicated on Novo’s potential to develop a drug that may be able to be used as a treatment specifically targeting obesity. We realised a breakthrough in this area would be hugely significant given the far larger addressable market for weight-loss than diabetes management and the lack of efficacious products.
Of course, there was no guarantee that this potential would be realised. Drug development is unpredictable, and goals can be missed. But the stability afforded by the investment trust structure meant we could take a long-term view and engage with the firm, understand its approach, and wait for the long-term R&D programs to reach commercial success.
That promise came to full fruition in 2021, when Novo launched its Wegovy drug in the US, with demand almost instantly dramatically outstripping supply. To the present day, the demand for this product still materially outstrips the amount that Novo can supply.
Our ability to stick with Novo Nordisk since 2017 was aided by our investment trust structure.
Unlike an open-ended fund, trusts have a fixed pool of capital and investors can gain exposure to them via the purchase of shares. This means that when investors sell shares in an investment trust, the amount of money the trust manager can invest is not impacted. In contrast, open-ended fund managers may have to sell some holdings to meet investor redemptions.
In the case of our investment in Novo, our structure allowed us to adopt a long-term view, and buy into a new chief executive’s vision and his firm’s potential just one month after he started in January 2017.
Buying in when the stock was valued at a price/earnings multiple of 15x – having fallen from 30x – has proven hugely beneficial for the trust. Novo’s shares have risen 552% since we took our initial position, well above the 56% return from the broader market.
Of course, it won’t necessarily be plain sailing from here. While enjoying a first-mover advantage, Novo is not operating in a vacuum and others will inevitably join the fray.
Indeed, US rival Eli Lilly submitted a proposal to the Food and Drug Administration in June for approval of its tirzepatide as a weight-loss treatment. It is already sold in the US for treatment of diabetes under the brand Mounjaro.
This means that Novo will soon face competition, although we believe this is a healthy development in such a large and underserved market.
A further potential risk facing Novo is its ongoing supply chain challenges, driven in part by the outsized demand it has seen for Wegovy. It has sought to reduce this risk by broadening its manufacturing base, opening several production lines with two different contractors. The proactivity of its management in the face of this challenge gives us confidence in the ongoing investment case for Novo Nordisk.
Innovation has been at the heart of Novo’s story over the past decade and investors must be able to take a long-term view if they want to benefit from this powerful driver.
Innovation is about constantly pushing the boundaries, but at the cutting-edge steps can be small and progress piecemeal. Thanks in part to the benefits of the investment trust structure, Henderson EuroTrust can wait for businesses to become successful when we are confident that they are deploying a sensible strategy for achieving their aims.
An investment trust is a form of investment fund, specifically a publicly traded collective investment scheme that invests its shareholders’ money in the shares of other companies.
An investment in a single financial instrument or group of financial instruments, such as shares or bonds. For example, a portfolio can have a position in a technology company or hold several different stocks to take a position in the technology sector.
Price-to-earnings (P/E) ratio
A popular ratio used to value a company’s shares, compared to other stocks, or a benchmark index. It is calculated by dividing the current share price by its earnings per share. It is calculated by dividing the current share price (P) by its earnings per share (E).
References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.
Not for onward distribution. Before investing in an investment trust referred to in this document, you should satisfy yourself as to its suitability and the risks involved, you may wish to consult a financial adviser. This is a marketing communication. Please refer to the AIFMD Disclosure document and Annual Report of the AIF before making any final investment decisions. Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. Tax assumptions and reliefs depend upon an investor’s particular circumstances and may change if those circumstances or the law change. Nothing in this document is intended to or should be construed as advice. This document is not a recommendation to sell or purchase any investment. It does not form part of any contract for the sale or purchase of any investment. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.
Issued in the UK by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Henderson Investors International Limited (reg no. 3594615), Janus Henderson Investors UK Limited (reg. no. 906355), Janus Henderson Fund Management UK Limited (reg. no. 2678531), (each registered in England and Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial Conduct Authority) and Janus Henderson Investors Europe S.A. (reg no. B22848 at 2 Rue de Bitbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier).
Janus Henderson and Knowledge Shared are trademarks of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc
Please read the following important information regarding funds related to this article.
- If a Company's portfolio is concentrated towards a particular country or geographical region, the investment carries greater risk than a portfolio that is diversified across more countries.
- The Company may have a particularly concentrated portfolio (low number of holdings) relative to its investment universe - an adverse event impacting only a small number of holdings can create significant volatility or losses for the Company.
- Where the Company invests in assets that are denominated in currencies other than the base currency, the currency exchange rate movements may cause the value of investments to fall as well as rise.
- This Company is suitable to be used as one component of several within a diversified investment portfolio. Investors should consider carefully the proportion of their portfolio invested in this Company.
- Active management techniques that have worked well in normal market conditions could prove ineffective or negative for performance at other times.
- The Company could lose money if a counterparty with which it trades becomes unwilling or unable to meet its obligations to the Company.
- Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- The return on your investment is directly related to the prevailing market price of the Company's shares, which will trade at a varying discount (or premium) relative to the value of the underlying assets of the Company. As a result, losses (or gains) may be higher or lower than those of the Company's assets.
- The Company may use gearing (borrowing to invest) as part of its investment strategy. If the Company utilises its ability to gear, the profits and losses incurred by the Company can be greater than those of a Company that does not use gearing.